Ultrasound and digital breast tomosynthesis find more cancers than just 2D mammography.
Ultrasound and digital breast tomosynthesis (DBT) detect more cancers than 2D mammography alone, according to a study published in The Breast.
Researchers from Korea sought to determine the percentage of breast cancers detected by screening ultrasound that were detectable by full-field digital mammography (FFDM) and DBT.
A total of 84 women with negative mammograms, but who had breast cancer subsequently detected by ultrasound were initially included in the study. All underwent both FFDM and DBT. Forty-one women were left in the study after the researchers excluded women with overt suspicious findings on repeat mammography and ineligible cases. Three radiologists, blinded to tumor location, read the images.[[{"type":"media","view_mode":"media_crop","fid":"41850","attributes":{"alt":"breast imaging","class":"media-image media-image-right","id":"media_crop_1507659893221","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4482","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 150px; width: 150px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"©karelnoppe/Shutterstock.com","typeof":"foaf:Image"}}]]
In the unblinded review, there were 25 visible cancers (61%) on FFDM and 34 (82.9%) on DBT. However, with the blinded reviews, the radiologists detected 22 (53.7%) on DBT and 11 (26.8%) on FFDM. “The dominant lesion type was “focal asymmetry” on DBT (39.0%) and “asymmetry” on FFDM (31.7%),” the authors wrote.
The authors concluded that both ultrasound and DBT detected more than half of cancers not found on 2D mammography, with an additional 29% of cancers visualized on DBT, when the radiologists were aware of the area of concern.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.